Memorial Park, which is currently undergoing a master plan renovation, and other Houston parks can be a great opportunity for introducing urban conservation inside the city limits. Rendering courtesy of Nelson Byrd Woltz

The Houston toad is a species that was discovered in Harris County in the 1950s. It has a very distinct, loud call that reverberates at quite a high pitch. But the Houston toad's call hasn't been heard in the city of Houston for almost 50 years. The species is locally extinct and critically endangered elsewhere. In fact, it's the most endangered amphibian in North America, says Cassidy Brown Johnson, a Rice University lecturer and president of the Coastal Prairie Partnership.

"When we think about extinction, we think of the dodo bird or the woolly mammoth," Johnson says. "But extinction is happening right underneath our noses."

The Houston Zoo has a breeding facility for Houston toad, but other than that, it's extremely unlikely that the Houston toad will ever reside naturally in its namesake city.

"We have modified the environment so heavily, that it'd be a bit of a dicey thing to do [to reintroduce the species] because there are so few of them, it's better to focus on an environment where it's still OK for them," Johnson says. The largest population of the Houston toad is actually in Bastrop, however due to the Bastrop fires in 2011, the species is only just recently back to a good place even there.

Johnson is giving a free lecture in April at Rice regarding extinction, where she'll bring her Astros-named Houston toads, Springer and Julia Morales, as her teacher aids.

Changing tides in conservation
As cities like Houston continue to be developed, scientists and researchers are challenged with finding new ways to effect conservation. Johnson says within the industry, there's been a shift in thinking when it comes to preserving nature.

"There's a new burgeoning movement in conservation called urban conservation," she says. "For a long time, if you talked to the traditional conservationists, the idea of conservation is to protect big spaces — the national and state park systems are the perfect example."

But large parks are expensive and a huge undertaking. It's still the strongest form of conservation, but introducing conservation efforts in a city — perhaps in some of Houston's parks, like Memorial Park or Hermann Park — helps not only the species of animals involved, but also educates the local population and forms a connection with residents.

"That has a twofold kind of benefit," Johnson says. "It protects the greenspace so species to live with us, and then also it makes the connection to this place we try to protect."

Of course, this type of effort is new, and there's not a lot of data to show how this would affect the ecosystem and its species, from the migratory and genetic diversity standpoints. Despite the lack of data, Johnson says this type of effort needs to happen.

"We're going to continue to manipulate the world, and maybe if we started thinking about this now, that we can get to a point were we understand enough were we can make these some sort of functioning ecosystem," she says.

Part of the shift in thinking about these ecosystems has to do with new ways of tracking species and understanding their environments.

"Technology is helping us ask a lot of these questions," Johnson says. "Ecology is surprisingly complicated. There's so many variables. ... I think technology and our advance with computing is definitely going to help us understand it."

Using preservation to solve flooding
The educational component is also very important to conservation, and Johnson is making strides on campus with her class. Last year, her department and her class introduced a pocket prairie right on the Rice campus.

Before it was the fourth largest city in America, Houston was a prairie. That type of ecosystem — thick with prairie grass — is very absorbing when it comes to rain water.

"It's really surprising to people that the trees and all this lushness is actually all artificial," Johnson says. "We know that this ecosystem evolved with the cyclical flooding events that happened here."

This movement to bring back Houston's ancient ecosystem is a new focus on a few prairie conservationist groups — and even the Harris County Flood Control. This has been going on for a while, but recent flooding events have opened the eyes of people now looking for reliable solutions to flooding problems.

"After Hurricane Harvey, people started realizing that this might be one of the solutions we could actually investigate and see if it can help us," Johnson says. "A green space is going to absorb way more water than a parking lot."

Of course, there are other flood solutions being discussed — some even incorporating tech or even a tube system underground.

"Historically, there has been some budding of heads between the environment and technology, but I really think moving forward, those two fields have to work together. We need to use technology to save the environment," Johnson says. "I think Houston is one of the places where that conversation is starting to happen."

Missing the toads

Courtesy of Cassidy Brown Johnson

The Houston toad has been locally extinct since the 1970s.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”